News

Investigators in China developed a patch test designed for hair care products tailored to clinical needs such as those of patients with conditions like alopecia areata.

A meta-analysis found oral immunotherapy improves health-related quality of life post-food allergy treatment, but benefits during treatment remain unclear.

With this FDA approval, chenodiol tablets become the first approved drug to treat CTX, a rare lipid storage disease.

Patients with PBC and severe pruritus had worse HRQoL, greater rates of depression, and more sleep interference than those with mild/moderate pruritus.

The US supply of semaglutide and semaglutide 2.4 mg now meets or exceeds current and projected demand, ending the long-running shortages of these blockbuster drugs.

Alvotech and Teva announced that the biosimilar will be interchangeable with the reference after ustekinumab-auub’s exclusivity expires in April 2025.

These data suggest therapeutic modulation of IL-23 inhibitors for psoriasis in those who have shown stability may be a legitimate strategy to ensure efficacy and safety.

A study analyzed hypersensitivity reactions to biologics for atopic diseases, highlighting reaction types, severity, and biologic discontinuation rates.

The strategy detailed in the guidance aids the early identification of infants with biliary atresia and is intended for use between 2 and 4 weeks of life.

Iron deficiency was more common in acute versus chronic heart failure, with notable differences in detection by numerous recommended definitions.

These data were the result of a new network meta-analysis looking specifically at children with eczema, highlighting the hierarchy of effectiveness among systemic drugs.

A 46-member expert panel created a consensus anaphylaxis definition, overview, and clinical tool to aid clinicians in recognition and management across settings.

In this quiz, we test your knowledge of recommendations to prevent food allergy development in infants.

By week 52, remibrutinib and placebo-to-remibrutinib groups had similar levels of urticaria control.

Low and high second-trimester eGFR values were linked to adverse pregnancy outcomes, including preeclampsia, preterm birth, low birth weight, and fetal loss.

Clark describes visual and anatomic improvements with aflibercept 8 mg in the PULSAR extension study, with most patients achieving extended dosing regimens.

A phase 2b trial showed that, unlike patients with MDD, patients with treatment-resistant depression do not receive significant benefits from SPN-820.

Alpyn’s Investigational New Drug application’s clearance by the FDA for the new Zabalafin Hydrogel for atopic dermatitis follows positive phase 2a clinical findings.

This genome-wide meta-analysis demonstrated that changes in 2 parts of the genome both work to influence patients’ risk of frontal fibrosing alopecia (FFA).

The multidisciplinary care model included 7 co-located specialists who aided patient education, lifestyle intervention, and drug therapy strategies for MASH.

Chalmers discussed how brensocatib’s potential approval may transform the currently empty treatment landscape for bronchiectasis.

In this feature, 3 experts highlight their own research on new technological advances and their views on the benefits and drawbacks of artificial intelligence in dermatology.

In this quiz, we test your knowledge of recommendations for introducing dietary diversity to infants.

The first of two Phase 3 pivotal trials investigating sozinibercept, COAST completed its final week 52 visit in patients with wet AMD.

Amneal Pharmaceuticals launched mesalamine 800 mg delayed-release tablets for UC and received FDA approval for various lenalidomide doses for blood cancers.

This analysis highlights the major risk factors resulting in limited use of oral JAKi for patients with hidradenitis suppurativa, including smoking, obesity, hypertension, and age.

Pitolisant was evaluated for the supplemental indication in the phase 3 INTUNE study, which did not meet its primary outcome of reducing excessive daytime sleepiness.